Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

<p>Abstract</p> <p>Background</p> <p>Maintenance therapy with gefitinib notably improves survival in patients with advanced non-small cell lung cancer (NSCLC) and EGFR mutation-positive tumors, but the economic impact of this practice is unclear.</p> <p>Meth...

Full description

Bibliographic Details
Main Authors:	Zhu Jun, Li Te, Wang Xiaohui, Ye Ming, Cai Jian, Xu Yuejuan, Wu Bin
Format:	Article
Language:	English
Published:	BMC 2013-01-01
Series:	BMC Cancer
Subjects:	Gefitinib maintenance treatment EGFR mutation Cost-effectiveness Non-small cell lung cancer
Online Access:	http://www.biomedcentral.com/1471-2407/13/39

Similar Items

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature
by: Wen-Hao Tang, et al.
Published: (2011-09-01)

Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro
by: Wei WEI, et al.
Published: (2009-01-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
by: Shen Zhao, et al.
Published: (2020-11-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
by: Li D, et al.
Published: (2023-01-01)

Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations
by: Miaomiao Li, et al.
Published: (2022-06-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
by: Nan Wei, et al.
Published: (2020-08-01)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
by: Jiatao Liao, et al.
Published: (2021-06-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Clinico-economic evaluation of different treatment strategies in patients with non-small cell lung cancer and mutations in the EGFR gene
by: V V Ryazhenov, et al.
Published: (2016-09-01)

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)
by: Kazuhiro Asami, et al.
Published: (2022-06-01)

Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma
by: Datong CHU, et al.
Published: (2008-02-01)

Maintenance therapies for non small cell lung cancer
by: Normand eBlais, et al.
Published: (2014-08-01)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

Inhibition of EGFR Signaling Protects from Mucormycosis
by: Tonya N. Watkins, et al.
Published: (2018-09-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Effection and Mechanism of Radiosensitivity of Non-small Cell Lung Cancer Cell Line H358 Following Gefitinib Treatment
by: Jie DENG, et al.
Published: (2011-11-01)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
by: Verduyn S, et al.
Published: (2012-09-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
by: V V Ryazhenov
Published: (2017-01-01)

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
by: Koichi Goto, et al.
Published: (2023-03-01)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
by: Noorwati SUTANDYO, et al.
Published: (2019-09-01)

Favorable Response of Advanced Superior Sulcus Non-Small Cell Lung Carcinoma to Gefitinib for 11 years complicated by Interval Development of Small Cell Carcinoma of the Lung
by: Mark H. Cooper
Published: (2018-01-01)

Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma
by: Sian Yik Lim, et al.
Published: (2011-04-01)

EGFR-TKI plus bevacizumab as maintenance therapy for advanced lung adenocarcinoma: a retrospective study of 192 cases
by: HU Xueting, et al.
Published: (2021-04-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)